DL-TBOA
|
|
|
- CAS号:
- 205309-81-5
- 英文名:
- DL-TBOA
- 英文别名:
- DL-TBOA;DLTBOA,DL TBOA;BYOBCYXURWDEDS-IUCAKERBSA-N;D,L-THREO-B-BENZYLOXYASPARTATE;DL-threo-β-Benzyloxyasparticacid;DL-THREO-BETA-BENZYLOXYASPARTIC ACID;D-Aspartic acid, 3-(phenylmethoxy)-, (3R)-rel-
- 中文名:
- DL-TBOA
- 中文别名:
- 化合物 T11055
- CBNumber:
- CB2208679
- 分子式:
- C11H13NO5
- 分子量:
- 239.22
- MOL File:
- Mol file
|
|
|
DL-TBOA化学性质
-
沸点:
-
421.7±45.0 °C(Predicted)
-
|
-
密度:
-
1.392±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Desiccate at -20°C
-
|
-
溶解度:
-
<23.92mg/ml in DMSO;insoluble in H2O
-
|
-
形态:
-
solid
-
|
-
酸度系数(pKa):
-
2.07±0.27(Predicted)
-
|
-
颜色:
-
White
-
|
DL-TBOA性质、用途与生产工艺
DL-TBOA 是一种有效的不可运输的兴奋性氨基酸转运蛋白抑制剂，对兴奋性氨基酸转运蛋白 1 (EAAT1)，EAAT2 和 EAAT3 的 IC50 值分别为 70 μM，6 μM 和 6 μM。DL-TBOA 抑制表达人 EAAT1 和 EAAT2 的 COS-1 细胞摄取 [14C]谷氨酸，Ki 值分别为 42 μM 和 5.7 μM。DL-TBOA 以竞争性方式阻断 EAAT4 和 EAAT5，Ki 值分别为 4.4 μM 和 3.2 μM。
IC50: 70 μM (EAAT1), 6 μM (EAAT2) and 6 μM (EAAT3); Ki: 42 μM (human EAAT1), 5.7 μM (human EAAT2), 4.4 μM (EAAT4) and 3.2 μM (EAAT5)
DL-TBOA (70-350 μM; 48 hours; HCT116 and LoVo cell lines) treatment concentration-dependently enhances SN38-induced loss of viability. DL-TBOA reversed Oxaliplatin-induced loss of viability.
DL-TBOA (350 μM; 24 hours; HCT116 and LoVo cell lines) treatment decreases p53 induction by SN38 and oxaliplatin.
Cell Viability Assay
|
Cell Line:
|
HCT116 and LoVo cell lines
|
|
Concentration:
|
70 μM, 350 μM
|
|
Incubation Time:
|
48 hours
|
|
Result:
|
Enhanced SN38-induced, and counteracted Oxaliplatin-induced, cell death.
|
Cell Viability Assay
|
Cell Line:
|
HCT116 and LoVo cell lines
|
|
Concentration:
|
350 μM
|
|
Incubation Time:
|
24 hours
|
|
Result:
|
p53 induction by SN38 and oxaliplatin was decreased.
|
DL-TBOA (10 nmol; i.c.v.) to morphine-dependent rats significantly facilitates the expression of naloxone-precipitated somatic signs and conditioned place aversion.
|
Animal Model:
|
Male Sprague-Dawley rats (180-250 g)
|
|
Dosage:
|
1 nmol, 3 nmol, 10 nmol
|
|
Administration:
|
Intracerebroventricularly injection (i.c.v.)
|
|
Result:
|
Dose dependently facilitated various somatic signs induced by Naloxone (0.1 mg/kg)-precipitated morphine withdrawal.
|
DL-TBOA
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-107522 | DL-TBOA
DL-TBOA | 205309-81-5 | 10mM * 1mLin DMSO | 3190元 |
| 2024/04/30 | HY-107522 | DL-TBOA
DL-TBOA | 205309-81-5 | 10mg | 4500元 |
205309-81-5, DL-TBOA 相关搜索:
- 化合物 T11055
- 205309-81-5
- DLTBOA,DL TBOA
- BYOBCYXURWDEDS-IUCAKERBSA-N
- D-Aspartic acid, 3-(phenylmethoxy)-, (3R)-rel-
- DL-threo-β-Benzyloxyasparticacid
- DL-TBOA
- D,L-THREO-B-BENZYLOXYASPARTATE
- DL-THREO-BETA-BENZYLOXYASPARTIC ACID